Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence

被引：14

作者：

Parikh, Raunak ^{[1
,5
]}

Singer, David ^{[2
]}

Chmielewski-Yee, Elizabeth ^{[3
]}

Dessart, Christophe ^{[4
]}

机构：

[1] GSK, Global Med Affairs, Wavre, Belgium

[2] GSK, US Hlth Outcomes & Epidemiol, Philadelphia, PA USA

[3] GSK, Epidemiol & Patient Ctr Outcomes, Rockville, MD USA

[4] GSK, Clin Safety & Pharmacovigilance, Wavre, Belgium

[5] GSK, Bldg WN23-B2,Ave Fleming 20, B-1300 Wavre, Belgium

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 03期

关键词：

Autoimmune disease; completion rate; effectiveness; herpes zoster; immunodeficiency; immunosuppression; real-world evidence; recombinant zoster vaccine; post-herpetic neuralgia; safety; ADULTS AGED 50; HERPES-ZOSTER; SUBUNIT VACCINE; UNITED-STATES; IMMUNIZATION PRACTICES; RHEUMATOID-ARTHRITIS; ADVISORY-COMMITTEE; OLDER-ADULTS; IMMUNOGENICITY; TRANSPLANTATION;

D O I：

10.1080/21645515.2023.2263979

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The recombinant zoster vaccine (RZV) was licensed in the US for prevention of herpes zoster (HZ) in 2017. We conducted a literature search (January 1, 2017-August 1, 2023) using PubMed, Embase, and Scopus to consolidate the real-world evidence related to RZV. Overall, RZV effectiveness against HZ was high across the studied populations in real-world settings, including adults aged >= 50 years and patients aged >= 18 years with immunodeficiency or immunosuppression. Effectiveness was higher with two doses versus one dose, especially in elderly people and immunocompromised individuals. The safety profile of RZV was broadly consistent with that established in clinical trials. RZV does not appear to increase the risk of disease flares in patients with immune-mediated diseases. Approximately two-thirds of individuals received a second RZV dose within 2-6 months after the first dose. Collectively, RZV effectiveness against HZ was high, and these real-world studies reaffirm its favorable benefit-risk profile.

引用

页数：22

共 64 条

[1] Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older [J].

Ackerson, Bradley ;

Qian, Lei ;

Sy, Lina S. ;

Bruxvoort, Katia ;

Wu, Jun ;

Luo, Yi ;

Diaz-Decaro, John ;

Talarico, Carla ;

Tseng, Hung Fu .

VACCINE, 2021, 39 (06) :926-932

[2]

Anderson TC, 2022, MMWR-MORBID MORTAL W, V71, P80, DOI 10.15585/mmwr.mm7103a2

[3] Risk of Guillain-Barre syndrome following herpes zoster, United States, 2010-2018 [J].

Anderson, Tara C. ;

Leung, Jessica W. ;

Harpaz, Rafael ;

Dooling, Kathleen L. .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) :5304-5310

[4]

Barghash MH, 2020, J HEART LUNG TRANSPL, V39, P1501, DOI 10.1016/j.healun.2020.09.001

[5] Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial [J].

Bastidas, Adriana ;

de la Serna, Javier ;

El Idrissi, Mohamed ;

Oostvogels, Lidia ;

Quittet, Philippe ;

Lopez-Jimenez, Javier ;

Vural, Filiz ;

Pohlreich, David ;

Zuckerman, Tsila ;

Issa, Nicolas C. ;

Gaidano, Gianluca ;

Lee, Je-Jung ;

Abhyankar, Sunil ;

Solano, Carlos ;

Perez de Oteyza, Jaime ;

Satlin, Michael J. ;

Schwartz, Stefan ;

Campins, Magda ;

Rocci, Alberto ;

Llamas, Carlos Vallejo ;

Lee, Dong-Gun ;

Tan, Sen Mui ;

Johnston, Anna M. ;

Grigg, Andrew ;

Boeckh, Michael J. ;

Campora, Laura ;

Lopez-Fauqued, Marta ;

Heineman, Thomas C. ;

Stadtmauer, Edward A. ;

Sullivan, Keith M. ;

Alonso Alonso, Aranzazu ;

Anagnostopoulos, Achilles ;

Andreadis, Charalambos ;

Angelopoulou, Maria ;

Anttila, Veli-Jukka ;

Aoun, Mickael ;

Barista, Ibrahim ;

Berkahn, Leanne ;

Bloor, Adrian J. C. ;

Broady, Raewyn ;

Brossart, Peter ;

Buadi, Francis K. ;

Bulabois, Claude-Eric ;

Cantin, Guy ;

Cellini, Claudia ;

Chandrasekar, Pranatharthi Haran ;

Chauncey, Thomas ;

Cuneo, Antonio ;

Dadwal, Sanjeet Singh ;

Dickinson, Michael .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (02) :123-133

[6] Safety and reactogenicity of the recombinant zoster vaccine after allogeneic hematopoietic cell transplantation [J].

Baumrin, Emily ;

Izaguirre, Natalie E. ;

Bausk, Bruce ;

Feeley, Monica M. ;

Bay, Camden P. ;

Yang, Qiheng ;

Ho, Vincent T. ;

Baden, Lindsey R. ;

Issa, Nicolas C. .

BLOOD ADVANCES, 2021, 5 (06) :1585-1593

[7] Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study [J].

Berkowitz, Elchonon M. ;

Moyle, Graeme ;

Stellbrink, Hans-Juergen ;

Schuermann, Dirk ;

Kegg, Stephen ;

Stoll, Matthias ;

El Idrissi, Mohamed ;

Oostvogels, Lidia ;

Heineman, Thomas C. .

JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (08) :1279-1287

[8] Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination [J].

Bruxvoort, Katia J. ;

Qian, Lei ;

Wu, Jun ;

Florea, Ana ;

Ackerson, Bradley ;

Sy, Lina S. ;

Daily, Leticia Vega ;

Takhar, Harpreet ;

Tseng, Hung Fu .

OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (03)

[9] Flares in Rheumatoid Arthritis: Frequency and Management. A Report from the BRASS Registry [J].

Bykerk, Vivian P. ;

Shadick, Nancy ;

Frits, Michelle ;

Bingham, Clifton O., III ;

Jeffery, Iain ;

Iannaccone, Christine ;

Weinblatt, Michael ;

Solomon, Daniel H. .

JOURNAL OF RHEUMATOLOGY, 2014, 41 (02) :227-234

[10] Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older [J].

Cunningham, A. L. ;

Lal, H. ;

Kovac, M. ;

Chlibek, R. ;

Hwang, S. -J. ;

Diez-Domingo, J. ;

Godeaux, O. ;

Levin, M. J. ;

McElhaney, J. E. ;

Puig-Barbera, J. ;

Abeele, C. Vanden ;

Vesikari, T. ;

Watanabe, D. ;

Zahaf, T. ;

Ahonen, A. ;

Athan, E. ;

Barba-Gomez, J. F. ;

Campora, L. ;

de Looze, F. ;

Downey, H. J. ;

Ghesquiere, W. ;

Gorfinkel, I. ;

Korhonen, T. ;

Leung, E. ;

McNeil, S. A. ;

Oostvogels, L. ;

Rombo, L. ;

Smetana, J. ;

Weckx, L. ;

Yeo, W. ;

Heineman, T. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11) :1019-1032

← 1 2 3 4 5 6 7 →